NIFTY 50

COVID Vaccine: SEC seeks more information from Serum Institute and Bharat Biotech

Updated : December 30, 2020 08:48:47 IST

While UK has approved Astrazeneca vaccine, Indian government's nod for the vaccine may take some more time. The expert panel on vaccine is believed to have sought more information from Serum Institute, which is the India partner and has submitted an application for the vaccine dubbed "Covishield" in India.

Timsy Jaipuria reports that applications of both Bharat Biotech and Serum Institute were not considered for Emergency Use Authorization (EUA) today by the subject expert committee (SEC).

Jaipuria said SEC has sought more information on well-updated factsheets, prescribing information and additional information from Serum Institute, while Bharat Biotech has been asked to submit more data.

Watch video for more.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV

recommended for you